SDIX's Q2 Revenues Rise 4 Percent

The company's Life Science business improved 13 percent year over year as it expanded its product offerings and continued to invest in its Genomic Antibody technology.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories